UFP Technologies (NasdaqCM:UFPT) Q4 2025 Earnings call February 25, 2026 08:30 AM ET Company ParticipantsAndrew Cooper - Director of Equity ResearchJeff Bailly - Chairman and CEOJustin Ages - Director of Equity ResearchRon Lataille - VP, Treasurer, and CFOConference Call ParticipantsMax Michaelis - Equity Research AnalystNone - AnalystOperatorGood day, welcome to the UFP Technologies fourth quarter 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, pleas ...

分组1 - CeriBell, Inc. reported a quarterly loss of $0.36 per share, better than the Zacks Consensus Estimate of a loss of $0.43, representing an earnings surprise of +16.76% [1] - The company posted revenues of $24.78 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 4.40%, and compared to revenues of $18.53 million a year ago [2] - CeriBell, Inc. has surpassed consensus EPS estimates for four consecutive quarters [2] 分组2 - The stock has underperformed the market, losing about 8.9% since the beginning of the year, while the S&P 500 has declined by only 0.1% [3] - The current consensus EPS estimate for the coming quarter is -$0.37 on revenues of $26.01 million, and for the current fiscal year, it is -$1.46 on revenues of $112.76 million [7] - The Zacks Industry Rank for Medical - Products is in the bottom 45% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Core Insights - Solventum (SOLV) is set to release its fourth-quarter 2025 results on February 26, with previous earnings exceeding estimates by 4.90% and a trailing four-quarter average earnings surprise of 10.42% [1][3] Financial Estimates - The Zacks Consensus Estimate for Solventum's revenues is $1.96 billion, while the consensus for earnings is $1.50 per share [2] Performance Overview - The company is expected to report strong underlying momentum in Q4 2025, following a third quarter characterized by improved commercial execution and cost initiatives, although tariffs may negatively impact results [3][9] - Management raised full-year guidance to the high end of its organic growth range of 2-3% and adjusted EPS outlook from $5.88-$6.03 to $5.98-$6.08 [3][9] Segment Performance - MedSurg, the largest segment, achieved 1.1% organic growth in Q3, with Advanced Wound Care growing by 2.7% [4] - Infection Prevention and Surgical Solutions remained flat, indicating a reversal of earlier order timing benefits, while Dental Solutions saw a notable 6.5% organic growth [5][6] - Health Information Systems (HIS) posted 5.6% organic growth, driven by revenue cycle management software and favorable consulting milestones [8] Strategic Developments - The sale of the Purification & Filtration business in September increased the company's cash position by $4 billion, which is being utilized for debt reduction and potential acquisitions [9] - The company acquired Acera Surgical to enhance its MedSurg portfolio with synthetic tissue matrices technology [9] Margin and Cost Management - Gross margin in Q3 was 55.8%, impacted by a 130-basis-point tariff effect, with expectations of further tariff pressures in Q4 [11] - The "Transform for the Future" initiative aims for $500 million in annual savings over four years, which, along with supply chain efficiencies, is expected to support margin resilience [11]

Core Insights - Haemonetics reported quarterly earnings of $1.31 per share, exceeding the Zacks Consensus Estimate of $1.27 per share, and up from $1.19 per share a year ago [1] - The company achieved a revenue of $338.97 million for the quarter, surpassing the Zacks Consensus Estimate by 1.44%, although this represents a decline from $348.54 million in the same quarter last year [3] Earnings Performance - The earnings surprise for the recent quarter was +3.15%, following a previous surprise of +13.39% when earnings were $1.27 per share against an expectation of $1.12 per share [2] - Haemonetics has consistently surpassed consensus EPS estimates over the last four quarters [2] Stock Performance and Outlook - Haemonetics shares have declined approximately 17.7% since the beginning of the year, contrasting with a 0.5% gain in the S&P 500 [4] - The current consensus EPS estimate for the upcoming quarter is $1.30, with expected revenues of $334.48 million, and for the current fiscal year, the estimate is $4.93 on $1.32 billion in revenues [8] Industry Context - The Medical - Products industry, to which Haemonetics belongs, is currently ranked in the bottom 29% of over 250 Zacks industries, indicating potential challenges for stock performance [9] - Empirical research suggests that trends in earnings estimate revisions are strongly correlated with near-term stock movements, which may impact Haemonetics' future performance [6]

分组1 - ResMed reported quarterly earnings of $2.81 per share, exceeding the Zacks Consensus Estimate of $2.69 per share, and showing an increase from $2.43 per share a year ago, resulting in an earnings surprise of +4.59% [1] - The company achieved revenues of $1.42 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.30%, and up from $1.28 billion year-over-year [2] - ResMed has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has gained approximately 7% since the beginning of the year, outperforming the S&P 500's gain of 1.9% [3] - The company's earnings outlook is crucial for future stock performance, with current consensus EPS estimates at $2.75 for the coming quarter and $10.86 for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Products sector is currently in the bottom 37% of over 250 Zacks industries, which may impact stock performance [8]

Core Insights - Stryker Corporation (SYK) is set to announce its fourth-quarter 2025 results on January 29, with a previous earnings surprise of 1.59% [1] Q4 Estimates - The Zacks Consensus Estimate for earnings is $4.39 per share, reflecting a year-over-year increase of 9.5% [2] - Revenue consensus is projected at $7.13 billion, indicating a growth of 10.8% compared to the previous year [2] - Model estimates for total sales and adjusted earnings per share are $7.11 billion and $4.35, respectively [2] Factors to Note - Stryker is anticipated to report strong performance in Q4, driven by sustained procedural strength, robust capital demand, and successful product launches, despite tariff-related cost pressures [3] - Top-line growth is expected to stem from broad-based demand across Orthopedics, MedSurg, and Neurotechnology, along with improved execution at the Inari business [3][4] Revenue Growth Drivers - Organic revenue growth is likely supported by stable and resilient procedure volumes across various geographies [4] - Strong hospital balance sheets are facilitating capital spending, with Stryker exiting Q3 with a high backlog and strong order books [4] Margin and Cost Dynamics - Margin expansion efforts are expected to yield positive results through favorable product mix, manufacturing efficiencies, and disciplined SG&A [6] - However, tariff pressures and increased interest expenses from recent debt issuance may limit incremental margin growth [6][7] Segment Performance - Orthopedics is projected to be a key growth driver, with knee and hip businesses likely achieving high-single-digit organic growth due to robotic-assisted surgery adoption and Mako installations [8] - The "Other Ortho" category is expected to remain a significant contributor, supported by a robust capital environment [10] - MedSurg and Neurotechnology segments are likely to maintain strong momentum, benefiting from broad-based growth and specific product demand [11][13] Earnings Prediction Model - The current model does not predict an earnings beat for Stryker, as the Earnings ESP is -0.24% and the company holds a Zacks Rank of 3 [14][15]

Group 1 - The core viewpoint of the news is that Shangrong Medical (002551) has experienced a significant decline in both revenue and net profit for the first three quarters of 2025, indicating financial distress [2] - As of January 28, 2026, Shangrong Medical's stock closed at 3.83 yuan, down 2.3%, with a turnover rate of 3.13% and a trading volume of 191,200 hands, amounting to a total transaction value of 73.6461 million yuan [1] - The company's main business includes the production and sales of medical products, medical services, and health industry operations [2] Group 2 - For the first three quarters of 2025, Shangrong Medical reported a main revenue of 754 million yuan, a year-on-year decrease of 24.85%, and a net profit attributable to shareholders of -35.1253 million yuan, a year-on-year decline of 338.5% [2] - In the third quarter of 2025 alone, the company recorded a main revenue of 225 million yuan, down 39.25% year-on-year, and a net profit of -27.367 million yuan, reflecting a staggering year-on-year decrease of 4004.28% [2] - The company's debt ratio stands at 23.31%, with investment income of 10.2049 million yuan and financial expenses of -3.7891 million yuan, while the gross profit margin is reported at 14.35% [2]

Core Viewpoint - The financial performance of Shangrong Medical (002551) shows significant declines in revenue and net profit for the first three quarters of 2025, indicating potential challenges for the company moving forward [2]. Financial Performance - For the first three quarters of 2025, Shangrong Medical reported a main revenue of 754 million yuan, a year-on-year decrease of 24.85% [2]. - The net profit attributable to shareholders was -35.13 million yuan, reflecting a year-on-year decline of 338.5% [2]. - The net profit after deducting non-recurring gains and losses was -42.33 million yuan, down 1336.59% year-on-year [2]. - In Q3 2025, the company recorded a single-quarter main revenue of 225 million yuan, a decrease of 39.25% compared to the same quarter last year [2]. - The single-quarter net profit attributable to shareholders was -27.37 million yuan, a decline of 4004.28% year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was -29.81 million yuan, down 2776.04% year-on-year [2]. - The company's debt ratio stands at 23.31%, with investment income of 10.20 million yuan and financial expenses of -3.79 million yuan [2]. - The gross profit margin is reported at 14.35% [2]. Market Activity - As of January 19, 2026, Shangrong Medical's stock closed at 3.84 yuan, up 1.32%, with a turnover rate of 1.6% [1]. - The trading volume was 97,900 hands, with a total transaction value of 37.43 million yuan [1]. - On January 19, the net outflow of main funds was 2.14 million yuan, accounting for 5.71% of the total transaction value [1]. - Retail investors showed a net inflow of 2.19 million yuan, representing 5.84% of the total transaction value [1].

Core Viewpoint - The comparison between Envista (NVST) and Stryker (SYK) indicates that NVST is currently a more attractive option for value investors due to its stronger earnings outlook and favorable valuation metrics [1][2]. Valuation Metrics - Envista has a forward P/E ratio of 19.27, while Stryker's forward P/E is 23.99, suggesting that NVST is more reasonably priced relative to its earnings [4]. - The PEG ratio for NVST is 1.08, indicating a better valuation when considering expected earnings growth, compared to SYK's PEG ratio of 2.30 [4]. - Envista's P/B ratio stands at 1.29, significantly lower than Stryker's P/B ratio of 6.31, further supporting NVST's position as a better value option [5]. Investment Grades - Envista holds a Zacks Rank of 2 (Buy), while Stryker has a Zacks Rank of 3 (Hold), reflecting a more favorable earnings outlook for NVST [2]. - Based on valuation figures, Envista has a Value grade of B, whereas Stryker has a Value grade of C, indicating that NVST is the superior value option at this time [5].

Core Viewpoint - British medical products maker Smith & Nephew is set to acquire U.S.-based Integrity Orthopaedics in a deal potentially valued at up to $450 million [1] Company Summary - Smith & Nephew is a British company specializing in medical products [1] - The acquisition of Integrity Orthopaedics represents a strategic move to enhance Smith & Nephew's portfolio in the orthopedic sector [1] Financial Summary - The deal could be valued at up to $450 million, indicating a significant investment by Smith & Nephew in expanding its market presence [1]